DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022 as Editor’s Choice, on Life Sciences Review Magazine...
DelNova announces advances in the development of the First ever product to reverse complications arising from botulinum toxins, such as BOTOX®, Dysport®, XEOMIN®, and Jeuveau®, US patent and launch of STARTENGINE equity crowdfunding....
StartEngine allows anyone to invest in startups, private companies, and collectibles - like trading cards, comic books, and even fine wine! Now you can join Shark Tank’s Mr. Wonderful and Howard Marks, the co-founder of Activision, by investing....
Steve Yoelin, M.D. is a board-certified ophthalmologist based in Orange County, CA, with approximately 20 years of experience in minimally invasive medical aesthetics, such as dermal fillers, neurotoxins, and fat reduction....
DelNova’s patent portfolio covers key markets worldwide....
Watch the video presentation....
Presentation to highlight ReViVox™, DelNova's lead product candidate designed for treating complications resulting from undesirable muscle paralysis following botulinum neurotoxin (e.g. Botox®) procedures SAN DIEGO and CHICAGO, May 29, 2019 /PRNewswire/ -- DelNova, a biopharmaceutical company developing clinically validated molecules linked to advances in drug delivery, announced today that its...
